Interpace Biosciences Inc - SIC # 8011 - OFFICES AND CLINICS OF DOCTORS OF MEDICINE

Ticker Exchange SIC # Website Latest Ticker
IDXG Over the counter 8011 https://www.interpace.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Interpace Biosciences Inc

Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern - Nov 14th, 2022 9:41 pm
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting - Oct 20th, 2022 8:28 pm
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved - Sep 1st, 2022 9:18 pm
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc. - Aug 31st, 2022 9:30 pm
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved - Aug 15th, 2022 8:05 pm
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results - May 16th, 2022 8:15 pm
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience - May 11th, 2022 12:30 pm
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results - Mar 31st, 2022 8:15 pm
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests - Feb 22nd, 2022 2:00 pm